The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.

Cancer Med · 2021 · PMC7897940 · PMID 33340276

Europe PMC DOI

hedged sentences

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

did not reach statistical significancep = 0.066so close (0.05 < p ≤ 0.1)

Patients who achieved CRc and had FLT3 ‐ITD clearance ( n = 8) had a trend toward longer median OS (131.4 weeks; 95% CI: 18.6, not reached) than those who achieved CRc and did not have FLT3 ‐ITD clearance ( n = 41; median OS: 43.3 weeks; 95% CI: 27.7, 56.9; HR = 0.416 [95% CI: 0.159, 1.086]) and did not reach statistical significance ( p = 0.066; Figure 1 ).

also in 111,027 other papers

showed a trendno p-value reported

Patients who achieved morphologic remission with FLT3 ‐ITD clearance, defined as MRD negativity, showed a trend toward longer survival than those who achieved remission with persistence of the FLT3 ‐ITD clone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.